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Abstract
Background
Statin therapy is among the most effective treatments to improve short- and long-term mor-
tality after acute myocardial infarction. The use of statin, and the intensity of their use, has
not been described in acute myocardial infarction patients in China, a country with a rapidly
growing burden of cardiovascular disease.
Methods and Results
Using a nationally representative sample of patients with acute myocardial infarction admit-
ted to 162 Chinese hospitals in 2001, 2006 and 2011, we identified 14,958 patients eligible
for statin therapy to determine rates of statin use and the intensity of statin therapy, defined
as those statin regimens with expected low-density lipoprotein cholesterol lowering of at
least 40%, to identify factors associated with the use of statin therapy. Statin use among
hospitalized patients with acute myocardial infarction increased from 27.9% in 2001 to
72.5% in 2006, and 88.8% in 2011 (P<0.001 for trend). Regional variation in statin use cor-
respondingly decreased over time. Among treated patients, those receiving intensive statin
therapy increased from 1.0% in 2001 to 24.2% in 2006 to 57.2% in 2011(P<0.001 for trend).
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Patients without low-density lipoprotein cholesterol measured were less likely to be treated
with statin or to receive intensive therapy.
Conclusions
The use of statin therapy has dramatically increased over the past decade in Chinese
patients with acute myocardial infarction. However, half of patients still did not receive inten-
sive statin therapy in 2011.Given that guidelines strongly endorse intensive statin therapy
for acute myocardial infarction patients, initiatives promoting the use of statin therapy, with
attention to treatment intensity, would support further improvements in practice.
Introduction
China, a country of more than 1.3 billion people, faces a marked increase in the incidence of
acute myocardial infarction (AMI) with an estimated 23 million patients forecasted to experi-
ence AMI in 2030[1].This creates an imperative to optimize the use of evidence-based therapies
that improve patient outcomes. There is compelling scientific evidence demonstrating that
statin therapy reduces the rate of major adverse cardiovascular events in patients following
after AMI, with so-called “intensive” statin regimens offering the greatest benefit [2–7].
Clinical guidelines around the world strongly endorse statin therapy for all patients with
AMI [8,9]. More recently, guidelines endorsed by the American Heart Association and Ameri-
can College of Cardiology (AHA/ACC), recommended “high intensity” statin therapy (defined
as those regimens that lower low-density lipoprotein cholesterol (LDL-C) by at least 50%) for
patients with AMI [10]. The most recent Chinese guidelines for both non-ST elevation myocar-
dial infarction (published in 2007) and ST elevation myocardial infarction (published in 2010)
recommend statin therapy in all patients with AMI, but do not provide specific guidance about
the intensity of such therapy [11,12]. However, the Chinese dyslipidemia guidelines (published
in 2007) recommend “intensive” statin treatment in all patients with AMI regardless of baseline
LDL-C [13]. Notably, Chinese guidelines define intensive statin therapy as any statin regimen
that lowers LDL-C by at least 40% (as opposed to the 50% reduction required by the ACC/
AHA guidelines). This definition is congruent with observations that Chinese patients, as com-
pared with Caucasian patients, have lower LDL-C levels, and are more likely to experience
adverse reactions to statins[14].
A recent analysis of a nationally-representative sample of Chinese patients with STEMI,
statin use increased 3-fold between 2001 and 2011[15].Although this study provided initial
insights into the extent of statin use in China, it did not provide information about use in a
broad spectrum of patients with AMI, the intensity of statin therapy, or regional variation in
use. Given that health care resources are not evenly distributed in China [16], it is important to
understand if there are disparities in the use of statins among patients with AMI in China.
Finally, understanding factors associated with lack of statin use can inform efforts to improve
current prescription practices of statin therapy.
Accordingly, we performed a detailed analysis of statin utilization as part of a national qual-
ity assessment of AMI that uses data collected in the China Patient-Centered Evaluative
Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction (China
PEACE-Retrospective AMI Study).Specifically, our research objectives were to:(1) determine
current rates of and temporal trends in statin therapy, and intensive statin therapy, among eli-
gible patients hospitalized with AMI in China; (2) assess regional variation in statin therapy;
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(3) examine the use of statin therapy by LDL-C level; (4) analyze factors associated with the
lack of any statin therapy and intensive statin therapy in 2011.
Methods
Design Overview of China PEACE-Retrospective AMI Study
Full details of the design and methods of the China-PEACE Retrospective-AMI study have
been published previously [17]. In brief, we created a nationally representative sample of AMI
hospitalizations during 2001, 2006, and 2011 with a two-stage random sampling design. In the
first stage, we identified hospitals using a simple random sampling procedure within each of
the 5 study strata: Eastern-rural, Central-rural, Western-rural, Eastern-urban, and Central/
Western-urban regions. Since hospital volumes and clinical capacities differ between urban
and rural areas as well among the three official economic-geographic regions (Eastern, Central,
and Western) of Mainland China, we combined Central and Western urban regions together
given their similar per capita income and health services capacity. According to government
documents, there were 6623 non-military hospitals in 2011. We excluded prison hospitals, spe-
cialized hospitals without a cardiovascular disease division, and traditional Chinese medicine
hospitals. In the 3 rural strata, the sampling framework consisted of the central hospital in each
of the predefined rural regions (2010 central hospitals in 2010 rural regions). In each of the 2
urban strata, the sampling framework consisted of the highest-level hospitals in each of the pre-
defined urban regions (833 hospitals in 287 urban regions) (Fig 1). We randomly sampled all
the central hospitals in rural regions and all of the highest-level hospitals in urban regions, and
excluded hospitals that neither admitted patients with acute myocardial infarction or refused
to participate. Since the majority of hospitals in China are publicly owned and administered,
hospital closure is rare. The study cohort should be most representative of national treatment
patterns and outcomes in 2011. Therefore, we selected representative hospitals from 2011 to
reflect current practices and traced this cohort of hospitals back to 2006 and 2001 to describe
temporal trends. In the second sampling stage, we identified cases based on the local hospital
database for patients with AMI in each year at each sampled hospital using systematic random
sampling procedures. In each of the 5 study strata, we determined the sample size required to
achieve a 2% precision for describing the primary outcome, in-hospital mortality, which we
had estimated to be approximately 9% in urban hospitals and 7% in rural county-level hospi-
tals. We doubled the cluster sizes for 2011 to improve precision in the description of contem-
porary hospital-level treatment patterns and outcomes. Patients with AMI were identified
using International Classification of Diseases—Clinical Modification codes, including versions
9 (410.xx) and 10 (I21.xx)–information that the Ministry of Health in China requires to be
included in medical charts. When this data was unavailable, site coordinators manually
searched the hospital’s written log to identify hospitalizations for AMI. Only patients with a
definite discharge of AMI were included in the study sample. In any case where the diagnosis
of AMI was unclear, the site coordinator reviewed the original medical records.
Data were collected via standardized central medical record abstraction using standardized
data definitions. We adopted rigorous monitoring at each stage to ensure data quality. Data
abstraction quality was monitored by randomly auditing 5% of records, with overall accuracy
of the variables being more than 98% [17].
The central ethics committee (Ethics Committee of Fuwai Cardiovascular Hospital) at the
China National Center for Cardiovascular Diseases approved the China PEACE-Retrospec-
tive AMI Study. All collaborating hospitals accepted the central ethics approval except for
five hospitals, which obtained local approval by internal ethics committees (Ethics Commit-
tee of Jilin Province People's Hospital, Ethics Committee of Tianjin Medical University
Statin Use for Patients with AMI in China
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General Hospital, Ethics Committee of HuaXin Hospital, First Hospital of Tsinghua Univer-
sity, Ethics Committee of Affiliated Zhongshan Hospital of Dalian University, Ethics Com-
mittee of The First People's Hospital of Guangyuan).Consent form was not required because
we got data from retrospective medical chart review. Participating hospitals copied and
Fig 1. Flow Diagram of Study Sample.
doi:10.1371/journal.pone.0150806.g001
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transmitted the records to the NCCD after de-identification. The study is registered at www.
clinicaltrials.gov (NCT01624883).
Study Sample
We sampled 175 hospitals, of which 7 were excluded because they did not admit patients with
AMI and 6 declined to participate. Within the 162 remaining hospitals, there were 31,601 hos-
pitalizations for AMI in 2001, 2006 and 2011, from which we sampled 18,631 cases and
acquired medical records for 18,110 cases (97.2%). After exclusion of cases not appropriate for
study (including uninterpretable medical charts, duplicate cases, non-AMI diagnoses, cases not
within study periods, and AMI that occurred during hospitalization), we identified 16,100
patients with a definitive discharge diagnosis of AMI that were representative of all patients
hospitalized for AMI in China in 2001, 2006, and 2011. We excluded the following patients:
who died within 24 hours (n = 508), were transferred out within 24 hours (n = 299), were dis-
charged within 24 hours (n = 334), because these patients may not have the opportunity to
receive statin therapy. Among the remaining patients, we excluded patients who had a docu-
mented contraindication to statin that was described by the physician in the medical record
(n = 1), 14,958 patients with AMI, who were eligible for statin therapy remained and were
included in our analysis (Fig 1): 2198 (14.7%) were hospitalized for AMI in 2001, 4159 (27.8%)
in 2006 and 8601 (57.5%) in 2011.
Variables
We abstracted information about patient demographics (age, gender), cardiovascular risk fac-
tors (hypertension, diabetes, dyslipidemia, smoking), medical history (myocardial infarction,
ischemic stroke, hemorrhagic stroke), presenting symptoms(chest pain, cardiac arrest, cardiac
shock), laboratory results, diagnostic procedures, treatments, timing of care delivery and hospi-
tal outcomes from the medical record; the full details of the medical record abstraction have
been described previously [17]. The presence of comorbidities, including hypertension, diabe-
tes, and dyslipidemia, were recorded when such conditions were documented by the treating
physicians in the hospital medical record (admission notes, discharge diagnosis or positive lab-
oratory test results). To ensure that all patients with dyslipidemia were identified, we further
assigned a diagnosis of dyslipidemia on the basis of lipid panels measured during AMI admis-
sion. Dyslipidemia was defined as total cholesterol greater than 5.18 mmol/L,LDL-C greater
than or equal to 3.37 mmol/L, or high-density lipoprotein less than 1.04 mmol/Lfor men or
less than 1.30 mmol/L for women [18].
Statin Therapy and Intensive Statin Therapy
The type and dosage of statin therapy were determined by reviewing the last physician order
before discharge or in-hospital death. Subsequently, we identified patients receiving intensive
statin therapy, which was defined as statins dosed at a level expected to lower LDL-C by at least
40% according to the Chinese guideline[13], rather than the ACC/AHA recommendation for
doses expected to lower LDL-C by at least 50% [10]. This difference reflects the lower average
LDL-C levels of Chinese and the concern about safety [14]. The details of statin regimens
grouped by intensity were shown in (S1 Table) [10,19].
Statistical analysis
Categorical variables were described as frequencies with percentages. We transformed two con-
tinuous variables (i.e. age and LDL-C level) into categorical variables according to clinically
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meaningful cutoff values. We categorized age by 10-year age groups (<55, 55–64, 65–74,75
years) and LDL-C levels by clinically meaningful cutoff values (<1.81, 1.81–2.59, 2.60–3.37,
>3.37 mmol/L). Missing age values, which occurred infrequently (0.1%), were imputed as the
overall median. To assess differences between patients with and without statin therapy, we
used chi-square testing for categorical variables.
To estimate the use of statin therapy among the entire Chinese population with AMI, we
applied weights proportional to the inverse sampling fraction of hospitals within each stratum,
and the sampling fraction of patients within each hospital to account for differences in the sam-
pling fraction for each time period. We also stratified the unweighted rate of statin therapy
among eligible patients by the five defined regions and baseline LDL-C level, separately. Trends
in the use of statin therapy over time were evaluated by Cochran-Armitage test for trend.
To adjust for multiple factors and identify factors associated with any statin therapy, a mul-
tilevel logistic regression model using generalized estimating equation to account for clustering
of patients within hospitals was used. In order to reflect current practice patterns, we restricted
this analysis to patients hospitalized in 2011.Candidate explanatory variables, which were
based on clinical judgment and literature review, included demographic characteristics (age
and gender), cardiovascular risk factors (hypertension, diabetes, dyslipidemia, smoker) medical
history (myocardial infarction, ischemic stroke, hemorrhagic stroke), clinical characteristics at
admission (chest discomfort, cardiac arrest, cardiac shock), in-hospital management(fibrinoly-
sis, percutaneous coronary intervention), AMI type (STEMI, NSTEMI), LDL-C level, eco-
nomic-geographic region characteristics and urban/rural region. Similarly, we examined
patient characteristics associated with receiving intensity statin therapy among patients who
were hospitalized in 2011 and had documented statin dosage. We included all above candidate
variables. We performed backward stepwise selection method (with a cutoff significance level
of 0.05) to determine variables for inclusion in the final model. Odds ratios (OR) and 95% con-
fidential intervals (CI) were reported for both logistic regression analyses. All tests of statistical
significance were 2-sided, with a P<0.05 considered statistically significant. Statistical analysis
was performed using SAS software (version 9.2, SAS Institute, Cary, NC).
Results
Study Sample
There were 14,958 patients with AMI in our study. The proportion of male patients was 70.3%.
Comorbidities were common, 60.5% of patients had dyslipidemia, 50.9%hypertension, and
20.3% diabetes. Additionally, prior cardiovascular disease was frequent, with 10.8% having a
history of myocardial infarction and 10.3% having history of ischemic stroke (Table 1).
Statin therapy and Intensive Statin Therapy
Notably, the proportion of eligible patients receiving any statin therapy increased over the past
decade from 27.9% (weighted rate 29.4%) in 2001, to 72.5% (weighted rate 74.8%) in 2006, and
then to 88.8% (weighted rate 90.7%) in 2011 (P<0.001 for trend).
The rate of statin therapy increased in all regions over time, and the variation in statin use
across regions decreased. In 2001, the rate of statin use ranged from 7.4% in Western-rural to
42.9% in Eastern-urban, but by 2011, it ranged from 78.1% in Central-rural to 92.3% in East-
ern-urban (Fig 2). Similarly, the rates of statin therapy increased overtime regardless LDL-C
level (S1 Fig).
There were significant changes in the type of statin use during the past decade. Simvastatin
was the most frequently used agent in 2001 (60.2%) and 2006(44.5%), but in 2011 atorvastatin
became the principal statin, accounting for 52.9% of use (S2 Fig).
Statin Use for Patients with AMI in China
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Table 1. Baseline Characteristics of the Study Cohort Stratified by Statin Therapy.
Characteristics Total
NO (%)
Statin Therapy
NO (%)
No Statin Therapy
NO(%)
P value
All eligible patients 14,958 11,268(75.3) 3690(24.7) <0.001
Demographic
Age, years 0.092
<55 3346(22.4) 2563(22.7) 783(21.2)
55–64 3562(23.8) 2710(24.1) 852(23.1)
65–74 4471(29.8) 3258(28.9) 1213(32.9)
75 3579(23.9) 2737(24.3) 842(22.8)
Gender
Female 4446(29.7) 3306(29.3) 1140(30.9) 0.073
CVD risk factors
Prior hypertension 7430(49.7) 5908(52.4) 1522(41.2) <0.001
Prior diabetes 2603(17.4) 2134(18.9) 469(12.7) <0.001
Prior dyslipidemia 9050(60.5) 7410(65.8) 1640(44.4) <0.001
Current smoker 5242(35.0) 4197(37.2) 1045(28.3) <0.001
Medical histories
Myocardial infarction 1615(10.8) 1267(11.2) 348(9.4) 0.002
Ischemic stroke 1534(10.3) 1159(10.3) 375(10.2) 0.831
Hemorrhagic stroke 184(1.2) 134(1.2) 50(1.4) 0.428
Clinical characteristics at admission
Chest discomfort 13751(91.9) 10467(92.9) 3284(89.0) <0.001
Cardiac arrest 176(1.2) 141(1.3) 35(0.9) 0.138
Cardiac shock 644(4.3) 462(4.1) 182(4.9) 0.031
AMI type
STEMI 12806(85.6) 9569(84.9) 3237(87.7) <0.001
Laboratory test
LDL-C level, mmol/L <0.001
< 1.81 1443(9.6) 1158(10.3) 285(7.7)
1.81–2.59 3677(24.6) 3030(26.9) 647(17.5)
2.60–3.37 3803(25.4) 3166(28.1) 637(17.3)
>3.37 2707(18.1) 2291(20.3) 416(11.3)
Unmeasured 3328(22.2) 1623(14.4) 1705(46.2)
Economic-geographic region <0.001
Eastern 8866(59.3) 6783(60.2) 2083(56.4)
Central 3195(21.4) 2246(19.9) 949(25.7)
Western 2897(19.4) 2239(19.9) 658(17.8)
Urban/Rural
Rural 5664(37.9) 3796(33.7) 1868(50.6) <0.001
Urban 9294(62.1) 7472(66.3) 1822(49.4)
Year <0.001
2001 2198(14.7) 613(5.4) 1585(43.0)
2006 4159(27.8) 3016(26.8) 1143(31.0)
2011 8601(57.5) 7639(67.8) 962(26.1)
AMI indicates acute myocardial infarction;
STEMI indicates ST-segment elevation myocardial infarction;
LDL-C indicates low density lipid cholesterol.
doi:10.1371/journal.pone.0150806.t001
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Among patients treated with statins (Table 2), the proportion of patients receiving intensive
statin therapy increased from1.0% in 2001 to 24.2% in 2006 and 57.2% in 2011(Fig 3).
Although the rates of intensive statin therapy increased in all regions, wide variation persisted
in 2011, ranging from 21.0% in the Central-rural region to 73.0% in Eastern-urban (P for over-
all<0.001) (Fig 4).
Factors associated with use of any statin therapy in 2011
In the multivariable model, several patient and hospital factors were associated with any statin
therapy in 2011 (Fig 5). Patients whose LDL-C was not measured during the hospitalization
were significantly less likely to receive statin therapy (OR = 0.66; 95% CI 0.47–0.93, P<0.001),
patients with LDL-C 2.6–3.37 mmol/L (OR = 1.52; 95%CI 1.18–1.95, P<0.001) or LDL-C
>3.37 mmol/L (OR = 1.72; 95% CI 1.21–2.45, P<0.001) were more likely to receive statin ther-
apy than those with LDL-C<1.81mmol/L. Smoking and hypertension were also associated
with more likely to receive statin therapy.
Factors associated with use of intensive statin therapy in 2011
In the multivariable model including patients receiving any statin therapy(Fig 6), intensive
therapy was used less often in women (OR = 0.85; 95%CI 0.74–0.98, P<0.001), patients with
prior ischemic stroke(OR = 0.80; 95%CI 0.65–0.98, P<0.001) and patients without LDL-C
measured (OR = 0.61; 95%CI 0.43–0.86, P<0.001). In contrast, patients receiving PCI were
more likely to receive intensity statin therapy (OR = 2.70; 95%CI 1.99–3.66, P<0.001).
After accounting for differences in patient factors, those hospitalized in rural hospitals were
also less likely to receive intensive statin therapy compared with those in urban hospitals
(OR = 0.37;95%CI 0.21–0.63, P<0.001). In addition, patients in Eastern region (the most devel-
oped region in China) were more likely to receive intensive statin therapy (OR = 2.39; 95% CI
1.11–5.12, P<0.001) compared with those in Western region.
Discussion
In this first national quality assessment of statin use among hospitalized patients with AMI in
China, we found a substantial increase in the use of these drugs among patients with AMI over
Fig 2. Proportion of Patients Receiving Statin therapy Stratified by Region. P for trend <0.001 for the
proportion of statin therapy in 2001, 2006 and 2011.P for trend <0.001 for the proportion of statin therapy in
different regions.WR indicatesWestern rural; CR indicates Central rural; ER indicates Eastern rural; C/WU
indicates Central/Western urban; EU indicates Eastern urban.
doi:10.1371/journal.pone.0150806.g002
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Table 2. Baseline Characteristics of Statin-Treated Patients Stratified by Treatment Intensity.
Characteristics Total NO (%) Intensive Statin Therapy NO (%) Less Intensive Statin Therapy NO (%) P value
All patients 11,010* 5106 (46.4) 5904 (53.6) 0.002
Demographic
Age, years
<55 2491(22.6) 1216(23.8) 1275(21.6) 0.826
55–64 2647(24.0) 1252(24.5) 1395(23.6)
65–74 3177(28.8) 1400(27.4) 1777(30.1)
75 2695(24.5) 1238(24.2) 1457(24.7)
Gender
Female 3230(29.3) 1378(26.9) 1852(31.4) <0.001
CVD risk factors
Prior hypertension 5921(53.8) 2848(55.8) 3073(52.0) <0.001
Prior diabetes 2446(22.2) 1272(24.9) 1174(19.9) <0.001
Prior dyslipidemia 7229(65.7) 3619(70.9) 3610(61.1) <0.001
Current smoker 4118(37.4) 2041(39.9) 2077(35.2) <0.001
Medical histories
Myocardial infarction 1239(11.3) 604(11.8) 635(10.8) 0.075
Ischemic stroke 1136(10.3) 511(10.1) 625(10.6) 0.319
Hemorrhagic stroke 132(1.2) 61(1.2) 71(1.2) 0.969
Clinical characteristics at admission
Chest pain 10224(92.9) 4757(93.4) 5457(92.4) 0.058
Cardiac arrest 137(1.2) 68(1.3) 69(1.2) 0.441
Cardiac shock 450(4.1) 216(4.2) 234(3.9) 0.481
AMI type
STEMI 9344(84.9) 4223(82.7) 5121(86.7) <0.001
Laboratory test
LDL-C level, mmol/L <0.001
< 1.81 1140(10.4) 529(10.4) 611(10.3)
1.81–2.59 2952(26.8) 1405(27.5) 1547(26.2)
2.60–3.37 3091(28.1) 1499(29.3) 1592(27.0)
>3.37 2251(20.4) 1137(22.3) 1114(18.9)
Unmeasured 1576(14.3) 536(10.5) 1040(17.6)
Economic-geographic region 0.872
Eastern 6585(59.8) 3436(67.3) 3149(53.3)
Central 2224(20.2) 843(16.5) 1381(23.4)
Western 2201(20) 827(16.2) 1374(23.3)
Urban/Rural
Rural 3708(33.7) 1165(22.8) 2543(43.1) <0.001
Urban 7302(66.3) 3941(77.2) 3361(56.9)
Year
2001 592(5.4) 6(0.1) 586(9.9) <0.001
2006 2956(26.8) 729(14.3) 2227(37.7)
2011 7462(67.8) 4371(85.6) 3091(52.4)
*Note: 11,268 patients received statin therapy; however, the dose was not documented in the medical record of 258 patients and were excluded from this
table, leaving11,010 patients whose statin dose was definitively recorded.
AMI indicates acute myocardial infarction;
STEMI indicates ST-segment elevation myocardial infarction;
LDL-C indicates low density lipid cholesterol.
doi:10.1371/journal.pone.0150806.t002
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the past decade. However, there is still a substantial opportunity for further improvement
because 10% of eligible patients were not treated with these potentially life-saving drugs in
2011. Additionally, among patients receiving statin therapy, almost half did not receive inten-
sive therapy as defined by Chinese practice guidelines. While there were gains in both rural
and urban regions, as well as all economic-geographic regions, notable variation persisted in
2011. Notably, patients receiving care in rural hospitals were significantly less likely to receive a
statin of any intensity.
The increase in statin use from 2001 and 2011 in China represents a substantial improve-
ment in the use of evidence-based care for patients with AMI. Several factors may have driven
this improvement. For example, accumulating evidence of benefit of statins led codification of
Fig 3. Statin Intensity Therapy among Patients with Statin Therapy in China. P for trend <0.001 for the
proportion of intensive statin therapy in 2001, 2006 and 2011. WR indicatesWestern rural; CR indicates
Central rural; ER indicates Eastern rural; C/WU indicates Central/Western urban; EU indicates Eastern
urban.
doi:10.1371/journal.pone.0150806.g003
Fig 4. Statin Intensity Therapy among Patients with Statin Therapy Stratified by Region. P for trend
<0.001 for the proportion of intensive statin therapy in different regions. WR indicatesWestern rural; CR
indicates Central rural; ER indicates Eastern rural; C/WU indicates Central/Western urban; EU indicates
Eastern urban.
doi:10.1371/journal.pone.0150806.g004
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statins use in guidelines [8,11, 20–21],and an increased awareness of the fact that statins are
simple and generally safe. In addition, the increasing coverage provided by medical insurance
programs and the decrease in out-of-pocket payment for statins may also contribute to the
improvements observed in our study [22, 23].
Despite high rates of statin use, intensive statin regimens, which are recommended by many
guidelines, were only used in just over half of patients with AMI in China in 2011. Similar gaps
have also been observed in the US [24], France [25], and Canada [26], although the higher
threshold for LDL-C lowering of 50% was used to defined intensive therapy in these countries.
Potential barriers to the greater use of intensive statin regimens could include physicians’ con-
cerns about dose-dependent adverse effects of statin [27, 28], an especially pertinent consider-
ation given the increased risk of adverse events among Chinese patients [14]. Moreover,
previous studies have shown that Asian patients need lower statin dosage to achieve the same
LDL-lowering efficacy [29], and the highest approved dosages of some statins are lower in
China than Western countries. Although these factors may discourage the use of higher dose
statin, we defined intensive therapy based upon the Chinese guidelines, which are more conser-
vative than US guidelines. Finally, the challenges in the structure of healthcare systems might
create barriers that impede best practice,. The suboptimal use of intensive statin therapy high-
lights an important opportunity to improve care and reduce disparities.
Additionally, certain patient groups were particularly likely to be untreated or under-
treated. Women were less likely to be treated with intensive statin therapy, a finding consistent
with a recent analysis in the United States [30]. Since some studies have shown that women
may experience more side effects from statin therapy compared with men [31, 32], the sex
Fig 5. Factors Independently Associated with Statin Use in 2011. Variables with significant association
with any usage of statin are shown along the vertical axis. The strength of effect is shown along the horizontal
axis with the vertical dotted line demarking an odds ratio of 1 (that is, no association); estimates to the right
(that is, > 1) are associated with greater likelihood of early statin use, while those to the left (that is, < 1)
indicate association with reduced likelihood of early statin use. Each square and line represents the point
estimate of the effect of that variable in the model, while the line shows the 95% confidence interval. CVD
indicates cardiovascular disease.
doi:10.1371/journal.pone.0150806.g005
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differences observed in our study may reflect physician’s concerns about the risks associated
with statin therapy. Patients with a history of ischemic stroke were less likely to receive inten-
sive statin therapy, which was consistent with a previous study report in China [33]. This may
reflect concerns about the possible association between statin therapy and hemorrhagic stroke,
the incidence of which is much higher in China than in the West [34]. Additionally, those with-
out LDL-C measurement were much less likely to receive any statin therapy as well intensive
statin therapy, a finding consistent with previous studies [35,36].Taken together with our com-
plementary finding that those with higher LDL-C were more likely to receive statin therapy,
our study supports the hypothesis that physicians’ decisions about statin use are still guided by
measurements of LDL-C, a practice that is not now endorsed by guidelines [37]. Educational
efforts are needed to emphasize the benefits of statin therapy for all patients with AMI who tol-
erate this treatment and to construct performance measures to support broader and more con-
sistent adoption of current guidelines for statin therapy.
While hospitals across all economic-geographical regions improved, disparities between
them persisted: patients treated in rural centers were less likely to receive intensive statin ther-
apy in 2011. A number of factors may explain this observation. Differences in per capita
income, which are marked between urban and rural, are likely to influence the utilization of
medical resources. Despite health care reforms, medical insurance still does not cover the full
cost of statin therapy [23], leaving patients with lower income at particular risk for under-use.
Another explanation for the differences in statin utilization according to hospital location is
Fig 6. Factors Independently Associated with Intensive Statin Therapy in 2011. Variables with
significant association with usage of intensive statin therapy are shown along the vertical axis. The strength
of effect is shown along the horizontal axis with the vertical dotted line demarking an odds ratio of 1 (that is, no
association); estimates to the right (that is, >1) are associated with greater likelihood of early statin use, while
those to the left (that is, <1) indicate association with reduced likelihood of early statin use. Each square and
line represents the point estimate of the effect of that variable in the model, while the line shows the 95%
confidence interval.
doi:10.1371/journal.pone.0150806.g006
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that many urban hospitals are staffed with cardiovascular specialists [16],and the availability of
practitioners with greater condition-specific expertise may explain higher rates of statin use. In
contrast, most rural hospitals, which together are responsible for the care of more than half of
China’s population, have limited clinical capacity for advanced cardiac care and limited fund-
ing [16]. Initiatives to improve statin utilization that emphasize rural hospitals could have an
important impact on the disparities noted in this national quality assessment.
This is the first nationally representative study evaluating trends and disparities for statin
utilization among patients with AMI hospitalized in China. The findings of our study have
important implications for efforts to understand past performance and to improve the quality
of AMI care in China. These findings will serve as the foundation for future national quality
improvement efforts to overcome the barriers for the appropriate use of intensive statin
therapy.
Several limitations of our study should be noted. First, as with all retrospective studies, it
was limited by the quality of documentation in the medical records. To ensure our approach to
data collection was accurate, we independently re-abstracted 5% medical records noting accu-
racy rates exceeding 98% and giving us great confidence in the accuracy of the abstraction pro-
cess. Second, it is possible that our approach underestimated the number of patients with
contraindications to statin therapy because there may have been poor documentation of con-
traindication in the medical chart, which could indicate another opportunity to improve the
transparency and quality of care. Third, we did not collect the information about statin therapy
before admission, which might influence decisions around statin use and dosing. Finally, we
did not collect other factors, such as physicians’ attitude about intensive statin therapy or
patients’ refusal of treatments, which have the potential to influence rates of statin utilization.
Conclusion
This national quality assessment found that the use of statin among patients with AMI in
China increased sharply over the past decade; however, several opportunities to improve care
persist, particularly with regards to the use of intensive statin therapy. Our findings highlight
an opportunity for better translation of evidence into clinical practice with a focus on more
consistent care throughout China.
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